RecruitingPhase 3NCT05136976
Rituximab Therapy in Anti-Myelin Associated Glycoprotein Patients With Characteristics of Good Responders
Studying Polyneuropathy associated with IgM monoclonal gammopathy with anti-MAG
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Centre Hospitalier Universitaire de Saint Etienne
- Principal Investigator
- Anne-Laure KAMINSKY, MDCHU de Saint-Etienne
- Intervention
- Rituximab infusion(drug)
- Enrollment
- 90 target
- Eligibility
- 18 years · All sexes
- Timeline
- 2023 – 2028
Study locations (15)
- CHU Brest - La cavale blanche, Brest, France
- CHU Grenoble - La tronche, Grenoble, France
- CHU Lille - Roger Salengro, Lille, France
- CHU Limoges - Dupuytren, Limoges, France
- HCL lyon, Lyon, France
- CHU La Timone - APHM, Marseille, France
- CHU Nancy- Hôpital central, Nancy, France
- Hôtel-Dieu et Hôpital GR Laënnec - CHU Nantes, Nantes, France
- CHU Nice - Pasteur, Nice, France
- APHP Pitié Salpêtrière, Paris, France
- APHP - Kremlin-Bicêtre, Paris, France
- CHU de Saint-Etienne, Saint-Etienne, France
- CHU Strasbourg - Hautepierre, Strasbourg, France
- CHU Toulouse - Pierre-Paul Riquet, Toulouse, France
- CHU Tours - Bretonneau, Tours, France
Collaborators
Ministry of Health, France
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT05136976 on ClinicalTrials.gov